|
1) Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci. 2003; 997: 229-39
|
|
|
|
2) Othman EE, Hornung D, Salem HT, et al. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007 Jun 18; [Epub ahead of print]
|
|
|
|
|
|
3) Sampson JA. The development of the implantation theory for the origin of peritoneal endometriosis. Am J Obstet Gynecol. 1940; 40: 549- 57
|
|
|
|
|
|
4) Oosterlynck DJ, Cornillie FJ, Waer M, et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991; 56: 45-51
|
|
|
|
|
|
5) Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002; 17: 2715-24
|
|
|
|
|
|
6) Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 2001; 75: 1-10
|
|
|
|
|
|
7) Gleicher N, Pratt D. Abnormal (auto)immunity and endometriosis. Int J Gynaecol Obstet. 1993; 40: 21-7
|
|
|
|
|
|
8) Matsuzaki S, Canis M, Darcha C, et al. Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am J Reprod Immunol. 1998; 40: 291-4
|
|
|
|
|
|
9) Fujiwara H, Konno R, Netsu S, et al. Localization of mast cells in endometrial cysts. Am J Reprod Immunol. 2004; 51: 341-4
|
|
|
|
|
|
10) Sugamata M, Ihara T, Uchiide I. Increase of activated mast cells in human endometriosis. Am J Reprod Immunol. 2005; 53: 120-5
|
|
|
|
|
|
11) Chopin N, Ballester M, Borghese B, et al. Relation between severity of dysmenorrhea and endometrioma. Acta Obstet Gynecol Scand. 2006; 85: 1375-80
|
|
|
|
|
|
12) Anaf V, Simon P, El Nakadi I, et al. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril. 2006; 86: 1336-43
|
|
|
|
|
|
13) Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science. 2005; 308: 1587-9
|
|
|
|
|
|
14) Itoga T, Matsumoto T, Takeuchi H, et al. Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis. Pathol Int. 2003; 53: 371-5
|
|
|
|
|
15) Konno R, Fujiwara H, Suzuki M. Effectiveness of leukotriene receptor antagonists for dysmenorrhea of endometriosis. Fam Med. 2004; 36: 8-9
|
|
|
|
|
|
16) Ziaei S, Zakeri M, Kazemnejad A. A randomaised controlled trial of vitamin E in the treatment of primary dysmenorrheal. BJOG. 2005; 112: 466-9
|
|
|
|
|
|
17) Rotondi M, Labriola D, Rotondi M, et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol. 2002; 23: 523-6
|
|
|
|
|
|
18) Vercellini P, Fedele L, Pietropaolo G, et al. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003; 9: 387-96
|
|
|
|
|
|
19) Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003; 80: 560-3
|
|
|
|
|
|
20) Blei F, Wilson EL, Mignatti P, et al. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993; 155: 568-78
|
|
|
|
|
|
21) Haney AF, Weinberg JB. Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate. Am J Obstet Gynecol. 1998; 159: 450-4
|
|
|
|
|
|
22) Bahamondes L, Petta CA, Fernandes A, et al. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception. 2007; 75: 134-9
|
|
|
|
|
|
23) Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002; 77: 684-92
|
|
|
|
|
|
24) Schindler AE, Christensen B, Henkel A, et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol. 2006; 1: 9-17
|
|
|
|
|
|
25) Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006; 2: 248-56
|
|
|
|
|
|
26) Shippen ER, West WJ Jr. Successful treatement of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril. 2004; 81: 1395-8
|
|
|
|
|
|
27) Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrozol and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005; 84: 300-4
|
|
|
|
|
|
28) Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses IL-1{beta}-induced IL-8 production, aromatase activation and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab. 2007; 92: 3213-8
|
|
|
|
|
|
29) Sesti F, Pietropolli A, Capozzolo T, et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil Steril. 2007 Apr 13; [Epub ahead of print]
|
|
|
|
|
|
30) Wu Y, Guo SW. Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2007; 14: 374-82
|
|
|
|
|
|
31) Guney M, Oral B, Karahan N, et al. Regression of endometrial explants in a rat model of endometriosis treated with melatonin. Fertil Steril. 2007 Jun 18; [Epub ahead of print]
|
|
|
|
|
|
32) Netsu S, Konno R, Odagiri K, et al. Oral Eicosapentaenoic acid supplementation as possible therapy for endometriosis. Fertil Steril. In press
|
|
|
|
|
|
33) Nisolle M, Casanas-Roux F, Anaf V, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril. 1993; 59: 681-4
|
|
|
|
|
|
34) Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005; 84: 1144-55
|
|
|
|
|
|
35) Ferrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006; 149: 133-5
|
|
|
|
|
|
36) Saito T, Yoshizawa M, Yamauchi Y, et al. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung/Drug Res. 2003; 53: 507-14
|
|
|
|
|
|
37) Pierzynski P, Swiatecka J, Oczeretko E, et al. Effect of short-term, low-dose treatment with tamoxifen in patients with primary dysmenorrhea. Gynecological Endocrinology. 2006; 22: 698-703
|
|
|
|
|
|
38) Olive DL. Role of progesterone antagonists and new selective progesterone receptor modulators in reproductive health. Obstet Gynecol Surv. 2002; 57: 55-63
|
|
|
|
|